Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CFO Asif Ali sold 58,629 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. This represents a 49.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Price Performance
NASDAQ PTGX opened at $140.06 on Monday. Protagonist Therapeutics, Inc. has a 1-year low of $62.24 and a 1-year high of $160.81. The firm has a market capitalization of $9.06 billion, a P/E ratio of 135.98 and a beta of 1.53. The business’s 50-day simple moving average is $145.17 and its 200-day simple moving average is $122.37.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. The firm had revenue of $213.47 million during the quarter, compared to the consensus estimate of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The company’s revenue for the quarter was up 3746.8% on a year-over-year basis. On average, equities research analysts expect that Protagonist Therapeutics, Inc. will post 4.22 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Protagonist Therapeutics
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Keating Financial Advisory Services Inc. acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $30,000. Allworth Financial LP acquired a new position in Protagonist Therapeutics in the second quarter worth $31,000. Quantbot Technologies LP acquired a new position in Protagonist Therapeutics in the second quarter worth $42,000. Harbor Investment Advisory LLC bought a new stake in Protagonist Therapeutics during the second quarter valued at $89,000. Finally, EverSource Wealth Advisors LLC increased its stake in Protagonist Therapeutics by 63.0% during the first quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $96,000 after purchasing an additional 352 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets.
Protagonist’s pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor.
Featured Stories
- Five stocks we like better than Protagonist Therapeutics
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
